Document is current
Any future updates will be listed below
-
Authors
Ramos, Ana Raquel
Bregni, Giacomo
Gillet, Nadia
Ando, Kunie
Bodart, Cyril
Vercauteren Drubbel, Alizée
Descampe, Louison
Moresi, Fabiana
Bisteau, Xavier
Verheye, Quentin
Pirard, Sheleya
Erneux, Christophe
Beck, Benjamin
-
Funding
Funding for this research was provided by:
Fonds de la Recherche Scientifique – FNRS (Chargé de recherche)
Fonds de la Recherche Scientifique – FNRS (Aspirant)
Fonds de la Recherche Scientifique – FNRS (Aspirant)
Fonds de la Recherche Scientifique – FNRS (Chargé de recherche)
Fonds de la Recherche Scientifique – FNRS (40021386 – PDR)
Televie (40012435)
Televie (40007654)
WEL Research Institute (FRFS-WELBIO-CR-2017S-01)
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 26 August 2025
First Online: 4 November 2025
Declarations
:
: All animal experiments were approved by the ULB Ethical Committee (protocols 668 N and 821 N). No human participants were involved, and no human samples were used in this study.
: Not applicable.
: B.B. is the inventor on a pending patent related to SHIP2/PLK1 combined inhibition in esophageal cancer. All other authors declare no competing interests.
